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Objectives: To compare the rate of inpatient admissions of pediatric patients with 
acute asthma that came through the emergency department (ED) visits and mean 
charges per ED visit between Medicaid patients and privately insured patients. To 
identify factors associated with hospital admissions through the ED among pediatric 
patients with asthma. MethOds: A retrospective analysis using 2010-2011 National 
Emergency Department Sample (NEDS), the largest all-payer hospital based ED data-
base in the United States (US), was conducted. All ED visits with a primary diag-
nosis of acute asthma for patients aged 2-17 years were identified using ICD-9-CM 
codes of 493.XX. ED visits with unknown destination were excluded. Multivariable 
logistic regression and Generalized Linear Mixed Model were used to compare the 
rate of hospital admissions through the ED and mean ED charges between asthma 
children with Medicaid vs private insurance. Results: A total of 110,964 pediat-
ric asthma related ED visits from 1,713 US EDs was identified (Medicaid patients: 
n= 69,410 (63%), mean age= 7yrs, 39.86% female; Private insured patients: n= 41,554 
(37%), mean age= 7yrs, 39.79% female). Of these occurrences, 96,307 (87%) were 
discharged and 14,657 (13%) were admitted to hospital after ED visits. After adjusting 
for demographic and clinical factors, privately insurance patients were 12% more 
likely to be admitted to hospital after ED visits compared to Medicaid patients. (Odds 
ratio= 1.12, [95% confidence interval: 1.13-1.32]). The mean charge per ED visit for 
Medicaid insured patients was $1,330, compared to $1,380 among private insured 
patients (p< 0.01). Other factors associated with hospital admissions through ED 
were younger age, severity, weekday visits, and urban-rural location of patient’s 
residence. cOnclusiOns: Compared to asthma children with Medicaid, privately 
insured pediatric patients had increased hospital admissions through ED and ED 
charges. In addition to insurance type, factors relating to severity and hospital char-
acteristics were related to hospital admissions through the ED.
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Objectives: To examine the mortality and rehospitalization rates among hospi-
talized U.S. Medicare patients diagnosed with pneumonia. MethOds: Using U.S. 
Medicare data, 30-day and 1-year mortality rates as well as rehospitalization rates 
were calculated for patients with a primary diagnosis of pneumonia (International 
Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] codes 
480.0-483.99 or 485-487) or a secondary discharge diagnosis of pneumonia with 
a primary diagnosis of respiratory failure (ICD-9-CM code 518.81) or sepsis (038.
xx). Patients with continuous enrollment in a fee-for-service Medicare health 
plan throughout the calendar year, and at least 2 years prior, were included in 
the study. Age- and gender-adjusted readmission rates were calculated by direct 
standardization of the U.S. population age ≥ 65 years in 2010 using gender-specific 
age groups. Results: The 30-day and 1-year mortality rates increased by 5.9% (17 to 
18 per 1,000 person-years) and 13.2% (38 to 43 per 1,000 person-years), respectively, 
from 2008 to 2012. The overall adjusted readmission rates were 3.82% in 2008, 3.93% 
in 2009, 3.98% in 2010 and 2011, and 3.17% in 2012. Men had higher readmission rates 
than women for all study years except 2011. Patients age 65-69 years had the highest 
readmission rates in 2008 (4.47%), 2009 (4.59%) and 2011 (4.77%). In 2010, patients age 
70-74 years (4.41%), and in 2012, patients who were age 75-79 years (3.73%) had the 
highest readmission rates. Black patients had the highest readmission rates in 2008 
(5.08%), North American Natives in 2009 (4.86%), other race in 2010 (5.87%), Hispanics 
in 2011 (5.70%) and North American Natives in 2012 (7.11%). cOnclusiOns: Among 
U.S. Medicare beneficiaries diagnosed with pneumonia, mortality rates were higher 
from 2009 to 2012 than in 2008. Overall, hospital readmission rates were lower in 
2012 than 2008, after adjusting for age and gender. Readmission rates varied across 
race and age groups.
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Objectives: Hospital readmissions among patients with COPD have contributed 
a considerable burden to the healthcare system as measured by increased hospital 
stays and healthcare expenditures. The objective of this study is to estimate the 
factors influencing 30-day readmissions among patients with COPD. MethOds: A 
multivariable logit regression was conducted for patients with COPD [ICD 9 code(s) 
491, 492 or 496] discharged to home or other facilities, utilizing the 2012 Truven 
MarketScan dataset (un-weighted n= 21,771). The outcome variable was a dichoto-
mous 30-day readmission, considering any type of readmission. The covariates 
included demographic variables, characteristics of index hospitalization and risk 
factors including prior hospitalization and comorbidities. Results: The 30-day 
readmission rate among patients with COPD was 6.8%. Elderly patients (65+) 
were 77% [Odd ratio (OR)= 0.23, p= 0.001] less likely to be readmitted than younger 
cohort (aged 18-34). Male patients were 19% (OR= 1.19, p= 0.010) more likely to be 
readmitted than female patients. Patients with HMO, POS and Comprehensive 
insurances were 135% more (OR= 2.35, p< 0.001), 28% less (OR= 0.72, p< 0.029) and 
70% less (OR= 0.30, p< 0.001) likely to be readmitted than those with PPO. Patients 
discharged to facilities, and to home under care were 162% (OR= 2.62, p< 0.001) 
and 25% (OR= 1.25, p= 0.028) more likely to be readmitted than those discharged 
to home. Patients with asphyxia and respiratory arrest, anemia, and tobacco use 
were more likely to be readmitted than those without by 28% (OR= 1.28, p= 0.016), 
22% (OR= 1.22, p= 0.023) and 20% (OR= 1.20, p= 0.020), respectively. In addition, an 
increase of hospitalizations in the previous year contributed to a 0.75% probability 
increase of 30-day readmissions (p< 0.001). A one-day extended index hospital 
duration of stain therapy were also conducted. All analyses will be conducted using 
SAS version 9.3. Results: The study included 19,060 Medicaid beneficiaries with 
newly-diagnosed COPD, out of whom 30.3% beneficiaries received statins during the 
1-year baseline period. Compared to adults without statin therapy, those with statin 
therapy had significantly lower rates of COPD-specific hospitalizations (4.7% vs. 
5.2%; p< 0.05), emergency room visits (13.4% vs. 15.4%; p< 0.001) and outpatient visits 
(41.4% vs. 44.7%; p< 0.001). Even after adjusting for observed selection bias with IPTW 
technique, adults with statin therapy were less likely to have COPD-specific hospital-
izations (AOR: 0.76; 95% CI: 0.66, 0.87), emergency room visits (AOR: 0.81; 95% CI: 0.75, 
0.89) and outpatient visits (AOR: 0.86; 95% CI: 0.80, 0.91) compared to those without 
statin therapy. Adults with multimorbidity and statin therapy were less likely to 
have COPD-specific outcomes. cOnclusiOns: Statin therapy was associated with 
reduction in COPD-specific outcomes. These findings may suggest beneficial effects 
of statin among newly diagnosed COPD patients and warrant further clinical trial 
investigation.
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Objectives: Self-medication in both rural and urban population in Pakistan is 
an increasingly growing concern. Both literate and illiterate people irrespective 
of age and gender practice self-medication, which is in more than 50% of cases 
inappropriate. The aim of this study was to survey over-the-counter availability 
of medicines and self- medication pattern among the rural and urban popula-
tion of Karachi, Pakistan. MethOds: Over 1300 volunteers of ages (between 
20-80 years) and both genders were surveyed for their self-medication pattern. 
Medicines were grouped as antimicrobials and non-antimicrobials. Results: 93% 
of volunteers confirmed the practice of self-medications and the frequency was 
higher in females (57%) as compared to males (43%), and the pattern was same 
in both urban and rural environment. The general symptoms for which medi-
cines were taken included head ache (80%), body pain (67%), fever (40%), disturbed 
bowel (83%) and flu/cough/cold (72%). Among the non-antimicrobial medicines, 
the most frequently used groups were aspirin, paracetamol, chlorpheniramine, 
pseudoephedrine, ibuprofen and metronidazole. 13 % of the individuals confirmed 
adverse effects of the medicines. Among the antimicrobial drugs, only antibiot-
ics were taken, and almost all classes and generations of antibiotics were taken. 
Oral formulations of penicillins, quinolones, and cephalosporins were frequently 
used as compared to other classes of antibiotics. However, not a single example 
of intravenous and intramuscular antibiotics was observed. 43% of the individuals 
confirmed that antibiotics were ineffective in their condition. cOnclusiOns: 
The unregulated over-the-counter availability of medicines and the practice of 
self-medication are increasingly growing threats to the health care system in 
Pakistan. The inappropriate medications not only add to mortality and morbidity, 
but also cause increased cost of treatments. Such habits must be shunned through 
legislation and community awareness.
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Objectives: To measure the effectiveness of adherence interventions for asthma 
controllers on medication adherence and acute hospitalization (emergency 
room [ER] and inpatient) in two Medicaid managed care organizations (MCOs) in 
Southeastern Pennsylvania (SEPA) and Lehigh/Capital-New West Pennsylvania 
(LCNWPA). MethOds: One-year follow-up analysis of prescription and hospitali-
zation member data with prescription fills for asthma controllers from January 1 
to December 31, 2012. Thirty various interventions—categorized as general inter-
ventions (GI) for all subjects and personalized interventions (PI) for higher-risk 
care-managed subjects—were implemented to improve 2013 adherence. Medication 
adherence (proportion of days covered [PDC]; baseline inclusion criterion: 20%–67%) 
and acute hospitalization rates (utilization per thousand members per year) were 
calculated at baseline and at one-year post-intervention. Results: Of 3,589 par-
ticipants (793 LCNWPA; 2,796 SEPA), 767 were PI subjects (196 LCNWPA; 571 SEPA). 
SEPA and LCWPA member profiles were demographically similar to one another, 
except regarding race and ethnicity. The PDC rate improvements for asthma con-
trollers were 4.86% for LCNWPA and 2.95% for SEPA (P< 0.01 for both), accompanied 
by significant reductions in ER visits (−9.2% and −8.2%, respectively; P< 0.01 for 
both); the SEPA cohort also experienced significantly reduced inpatient admissions 
(−21.7%; P= 0.02). Improvements in mean PDC were significantly greater in PI than 
GI subjects (LCNWPA: 11.42% vs. 2.70%, P< 0.01; SEPA: 7.35% vs. 1.82%, P< 0.01), but 
acute hospitalization rates were not statistically lower in PI than GI subjects due to 
selection bias. Subjects demonstrating improvements in 2013 PDC rates displayed 
comparable changes in acute hospitalization rates as their non-improving coun-
terparts. cOnclusiOns: Multifaceted MCO-implemented adherence interven-
tions significantly improved medication adherence rates in Medicaid participants, 
translating into significant reductions in acute hospitalization. These results were 
especially apparent in higher-risk subjects.
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Spiromax® inhaler was also investigated. MethOds: The eligible adult patient 
population was based on current confirmed UK asthma and COPD diagnosis rates, 
with the proportion receiving FDCs based on market research data.  Costs of FDCs 
and scheduled and unscheduled healthcare events were taken from publicly avail-
able UK sources.  Frequency of poor inhalation technique with the market-leading 
DPIs, and the associated increased risk of unscheduled healthcare events, were 
taken from a large (n=1,664) cross-sectional, Italian observational study, with the 
estimated reduction in the proportion of patients with poor inhalation technique 
with DuoResp® Spiromax® based on a conservative assumption. Results: The 
model estimated that 400,926 adult patients use Symbicort® Turbohaler® and 
357,008 Seretide® Accuhaler® annually and were therefore eligible for treatment 
with DuoResp® Spiromax®, with 174,403 and 123,168 of these exhibiting poor 
inhalation technique, respectively.  Assuming a hypothetical uptake of DuoResp® 
Spiromax® reaching 13% in year 4 and 5, and its current UK price, the model 
predicted drug cost savings totalling £65.57 million over five years.  Furthermore, 
64,845 unscheduled healthcare events could be avoided due to the predicted 
improvement in inhalation technique with DuoResp® Spiromax® compared with 
these DPIs, resulting in further savings of £4.78 million. cOnclusiOns: DuoResp® 
Spiromax® is likely to offer budgetary savings compared with market-leading 
DPIs, with further cost savings potentially resulting from improved inhalation 
technique.
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Objectives: To estimate and compare the use and frequency of medical resources 
needed in the treatment of exacerbation episodes in patients with COPD at out-
patient and inpatient care levels from a public Mexican institutional perspec-
tive, in this case insured patients from the “Instituto Mexicano del Seguro Social” 
(IMSS). MethOds: From January to December 2013, a retrospective study was 
performed to estimate the direct medical costs of COPD exacerbations. The level 
of acuteness and treatment patterns used for the study where the same as those 
defined by the institution (IMSS guideline). Patient records were retrieved from 
the open institutional electronic databases for a 11822 COPD patients cohort. 
Exacerbation episodes were classified according to the guideline. Inpatient and 
outpatient care was the criteria for assessing the use and frequency of medical 
resources, including relevant outcomes as hospitalization, physician visits, inten-
sive care unit, surgery, medication use, clinical studies among others. Unitary costs 
were obtained from public tabulators (2014 IMSS). Mean frequency values were 
weighted with its corresponding costs. Results: In 2013, 16122 episodes of exac-
erbation were reported by the studied subjects. Patients over 45 years represented 
97% of all cases; being those over 65 years the most frequent (81%). A mean average 
of 5.6 days of inpatient care was founded at the study horizon. Yearly weighted 
cost of treatment for outpatient and inpatient care was US$8,630 and US$51,259 
respectively. A unitary item costs analysis from the inpatient versus the outpa-
tient treatment groups founded a significant increase in medication use (+83%), 
specialty visits (+100%), surgery (+100%) among other items. cOnclusiOns: In 
the treatment of exacerbation episodes in patients with COPD, the aggregated 
cost per year of inpatient versus outpatient care was estimated to be 83% higher. 
Reducing the risk of exacerbation episodes with the right treatment choice would 
be relevant for Mexican institutions.
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Objectives: Allergic rhinitis (AR) affects 20% of the population, and 40% of these 
patients report a diagnosis of asthma. Previous work has shown that treatment of 
AR improves asthma control. The objective was to examine healthcare costs related 
to AR and asthma for patients either treated with MP29-02*, a novel intranasal for-
mulation of azelastine hydrochloride and fluticasone propionate in an advanced 
delivery system, or combination therapy with single ingredient intranasal antihis-
tamine (INA) and intranasal corticosteroid (INS) sprays. MethOds: A retrospective 
analysis of medical and pharmacy claims of a commercially-insured U.S. popula-
tion was performed to evaluate differences in costs between two treatment groups 
(MP29-02* and INA/INS combination therapy). Medical and pharmacy claims occurring 
between 9/1/2011-3/31/2014 were used. Inclusion criteria included a diagnosis of rhi-
nitis (defined by ICD-9 472.0, 477.xx), at least 1 claim for a prescription intranasal spray 
(designated as the index date) during the identification period (9/1/2012—12/31/2013), 
12 months pre-index and 6-months post-index continuous enrollment, and no pre-
index claims for an intranasal spray. Patients diagnosed with asthma (493.xx) during 
the observation period were flagged. Inverse propensity score weighting adjustment 
was used to control for demographic, comorbidity, geographical and seasonal attrib-
utes. Adjusted mean AR-related and asthma-related costs for 6-months post-index 
were compared. Results: Total medical and pharmacy costs for the MP29-02* cohort 
(n= 810) are $2,782, statistically significant lower than for INA/INS cohort (n= 726) with 
$3,493 (P= .0074). For the sub-cohort with asthma, the MP29-02* cohort (n= 109) had 
lower asthma-related pharmacy costs ($247 vs. $796, P= .0193) and lower total asthma-
related costs ($565 vs. $1068, P= .0311) compared to the INA/INS asthmatic sub-cohort 
(n= 113). cOnclusiOns: For individuals with asthma and rhinitis, MP29-02* is asso-
ciated with lower asthma-related costs compared to sequential INA/INS therapy in 
particular for pharmacy costs highlighting the economic impacts of formulation and 
delivery system in intranasal AR therapy. *Dymista
stay served to contribute to a 0.19% probability increase of 30-day readmissions 
(p< 0.001). cOnclusiOns: Several comorbidities and a previous record of hospi-
talizations served as risk factors for 30-day readmissions. Patients with these risk 
factors are vulnerable and merit special attention.
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Objectives: The societal economic burden of asthma was $56 billion (direct and 
indirect costs) in 2007. Inpatient costs represented 28%-43% of the total direct costs 
(excluding prescription costs). The objective of this study is to estimate the deter-
minants of 30-day hospital readmissions among patients with asthma. MethOds: 
A cross-sectional analysis was conducted for patients with asthma (ICD 9 code 
493) among all age groups utilizing the 2012 Truven MarketScan dataset. Patients 
discharged to home or other facilities were included (un-weighted n= 16,390). 
A multivariable logit model was employed where the outcome variable was a 
dichotomous 30-day readmission (any caused readmission). The covariates 
included demographic characteristics, length of stay at index hospitalization, 
past healthcare utilizations, and comorbidities. Results: Among patients 
with asthma, the readmission rate within 30 days after the index hospitaliza-
tion discharge was 4.8%. Older groups were more likely to be readmitted than 
younger group (17-34 aged): Odds ratio (OR)= 1.59 (35-44 aged, p= 0.023), 1.61 (45-
54 aged, p= 0.012) and 1.71 (55-64 aged, p= 0.007). Patients with HMO, PPO and 
Comprehensive insurances were 72% more (OR= 1.72, p< 0.001), 31% less (OR= 0.69, 
p= 0.031) and 68% less (OR= 0.32, p< 0.001) likely to be readmitted than those with 
PPO, respectively. Patients discharged to other facilities were 388% (OR= 4.88, 
p< 0.001) more likely to be readmitted than those discharged to home. Patients 
with connective tissue disease were 63% (OR= 1.63, p= 0.007) more likely to be 
readmitted within 30 days than those without. In addition, an increase of hospi-
talization in the prior year contributed to a 1.36% probability increase of 30-day 
readmissions (p< 0.001). cOnclusiOns: Patient groups vulnerable for 30-day 
readmissions after hospitalization were identified among patients with asthma. 
A comorbidity disease and a previous record of healthcare utilization were risk 
factors for 30-day readmission.
ReSPiRatoRy-Related diSoRdeRS – cost Studies
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Objectives: To estimate annual drug wastage (drug that is discarded without being 
administered to a patient) and associated costs incurred by a typical hospital due to 
the use of multi-unit-dose packaged COPD treatment devices in patients admitted 
for acute chronic obstructive pulmonary disease (COPD) exacerbation. MethOds: 
An economic model was built to evaluate the annual number of wasted doses and 
related costs associated with adult patients admitted to the hospital for an acute 
COPD exacerbation. Model inputs were based on a retrospective study of adults with 
COPD admitted to a university-affiliated hospital between January 2011 and June 2012 
(Sakaan, Am J Respir Crit Care Med. 2014). Wasted doses for the following comparators 
were assessed: albuterol, arformoterol, fluticasone, formoterol, ipratropium, tiotro-
pium, budesonide/formoterol, and fluticasone/salmeterol (all non-nebulized formu-
lations except arformoterol). Because arformoterol is available in a single-unit-dose 
package, no wastage was assumed. Pharmacy costs of wasted doses were calculated 
from number of doses wasted and publicly available wholesale acquisition cost per 
dose (Red Book™, 2014). Results: Based on a hospital with 500 COPD admissions 
per year, the estimated annual number of wasted doses was 18,045 (87%) at a cost of 
$69,103. Budesonide/formoterol, tiotropium, and fluticasone/salmeterol were most 
costly, representing an annual cost of $28,292, $17,686, and $17,366 in drug wastage, 
respectively. Arformoterol ($0), formoterol ($518), and fluticasone ($550) had the low-
est annual drug wastage costs. The highest drug wastage costs per patient were with 
fluticasone ($195) and budesonide/formoterol ($161), while the lowest drug wastage 
costs per patient were with arformoterol ($0) and albuterol ($17). cOnclusiOns: For 
patients admitted to the hospital with a COPD exacerbation, the use of multi-unit-
dose packaged devices may result in significant costs due to drug wastage that could 
be avoided with use of single-unit-dose packaged devices.
PRS17
the budget iMPact oF duoReSP® SPiRoMax® (budeSonide + FoRMoteRol 
FuMaRate dihydRate) coMPaRed With coMMonly PReScRibed dRy 
PoWdeR inhaleRS FoR the ManageMent oF aSthMa and chRonic 
obStRuctive PulMonaRy diSeaSe in the united kingdoM: iMPact oF 
inhalation technique
Lewis A.1, Blackney M.1, Torvinen S.2, Plich A.3
1Covance Inc., London, UK, 2Teva Pharmaceuticals Europe B.V, Amsterdam, The Netherlands, 
3Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
Objectives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihy-
drate) is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-
acting beta agonist (LABA) in a novel dry powder inhaler (DPI).  An economic 
model was developed to assess the budget impact of switching adult patients 
with persistent asthma and chronic obstructive pulmonary disease (COPD) from 
market-leading DPIs in the United Kingdom (UK)  - Symbicort® Turbohaler® and 
Seretide® Accuhaler®  - to DuoResp® Spiromax®.  The potential cost benefit 
of improved inhalation technique due to the innovative characteristics of the 
